BRIEF published on 12/05/2024 at 13:05, 1 year 4 months ago Theralase Technologies Expands Bladder Cancer Study in Canada Canada Expansion Clinical Study Bladder Cancer Ruvidar Theralase Technologies
PRESS RELEASE published on 12/05/2024 at 13:00, 1 year 4 months ago Theralase(R) Launches New Clinical Study Site in Canada St. Joseph's Healthcare Hamilton joins Theralase®'s clinical investigation for bladder cancer treatment. Theralase® develops light-activated Ruvidar™ drug for BCG-Unresponsive NMIBC CIS patients Theralase® Bladder Cancer BCG-Unresponsive NMIBC CIS RuvidarTM Clinical Study Site
BRIEF published on 11/27/2024 at 23:10, 1 year 5 months ago Theralase Releases 3Q2024 Financial Overview Private Placements R&D Expenses Theralase Financial Overview Revenue And Margins Study II Results
PRESS RELEASE published on 11/27/2024 at 23:05, 1 year 5 months ago Theralase(R) Release’s 3Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the nine-month period ended September 30, 2024, showcasing key financial and operational results. Conference call scheduled for December 4th Conference Call Financial Statements Operational Results Theralase® Technologies Inc. Study II
BRIEF published on 11/15/2024 at 13:05, 1 year 5 months ago Theralase Technologies Concludes Private Placement of $CAN 666,400 Private Placement Warrants Bladder Cancer Theralase Technologies Clinical Stage
PRESS RELEASE published on 11/15/2024 at 13:00, 1 year 5 months ago Theralase(R) Closes Non-Brokered Private Placement Theralase® Technologies Inc. successfully closes non-brokered private placement offering of units for cancer research and development funding Private Placement Offering Drug Development Clinical Study Cancer Research Theralase® Technologies Inc.
BRIEF published on 11/13/2024 at 00:28, 1 year 5 months ago Theralase Technologies Extends Warrant Expiry to 2027 TSX Venture Exchange Warrant Extension Cancer Treatment Theralase Technologies Pharmaceutical Development
PRESS RELEASE published on 11/13/2024 at 00:23, 1 year 5 months ago Theralase(R) Extends Warrants Theralase® Technologies Inc. intends to extend the expiry date of 1,000,000 share purchase warrants from Nov 17, 2024, to Nov 17, 2027. This extension is subject to TSXV approval TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 10/07/2024 at 13:05, 1 year 6 months ago Theralase Updates on Bladder Cancer Clinical Study FDA Approval Clinical Study Theralase Bladder Cancer Ruvidar
PRESS RELEASE published on 10/07/2024 at 13:00, 1 year 6 months ago Theralase(R) Provides Update on Bladder Cancer Clinical Study Theralase® Technologies Inc. provides update on bladder cancer clinical study for BCG-Unresponsive NMIBC CIS using Ruvidar™ drug activated by TLC-3200 Medical Laser System, achieving positive interim results Clinical Study Theralase® Bladder Cancer RuvidarTM BCG-Unresponsive
Published on 05/04/2026 at 10:30, 26 minutes ago Storm Exploration Plans Drill Program to Test VMS Target at Gold Standard
Published on 05/04/2026 at 01:40, 9 hours 16 minutes ago New Head of Corporate Affairs and Sustainability
Published on 05/02/2026 at 21:00, 1 day 13 hours ago GECC Subsidiary Provides Update on its Lawsuit for Damages Against the Lender of the Atmosphere Project
Published on 05/02/2026 at 01:30, 2 days 9 hours ago Uraniumx Reports Strong Financial Position Ahead of Spring Drill Program
Published on 05/02/2026 at 00:50, 2 days 10 hours ago CoTec Announces Annual Stock Option, Restricted Share Unit And Deferred Share Unit Grants
Published on 05/04/2026 at 09:05, 1 hour 50 minutes ago Hach Launches Next-Generation DR4900 Spectrophotometer, Setting a New Industry Standard for Fast, Error-Free Water Analysis
Published on 05/04/2026 at 09:51, 1 hour 4 minutes ago GUILLEMOT CORPORATION: Weekly report share buyback From April 27th 2026 to May 1st 2026
Published on 05/04/2026 at 08:45, 2 hours 11 minutes ago Air Liquide divests its biogas production activities in four countries
Published on 04/30/2026 at 20:00, 3 days 14 hours ago AMA Corp PLC : FY 2025 Earnings & Q1 2026 Revenue
Published on 04/30/2026 at 19:16, 3 days 15 hours ago AXA announces the results of its Shareholders' Meeting
Published on 04/30/2026 at 19:00, 3 days 15 hours ago Capital increase through exercise of subscription rights
